
|Articles|January 19, 2021
Parenteral Subvisible Particle Testing
Author(s)Entegris
This paper details various USP subvisible particulate tests used to assure the minimization of particle counts in intravenous injections and the requirements and technologies used to meet them.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5